BlueRock’s neuronal stem cell therapy for Parkinson’s disease is first to show positive results in Phase I clinical study::Investigational Bemdaneprocel (BRT-DA01) was well tolerated with no major safety issues in all 12 patients through one year Assessment of secondary endpoints demonstrates feasibility of transplantation and evidence of cell survival and engraftment Phase II clinical study expected to begin enrolling patients in H1 […]
You must log in or register to comment.
This is great news, but N=12 is a really small study group!
That is a small group, but the results look promising. I hope they’re able to scale up quickly.
Two of my best friends have Parkinson’s.
Agreed!
